Early clinical results using blocking agents against the human cell surface receptor PD-1 and its ligants PDL-1 and PDL-2, point to unprecedented rates of long lasting anti-tumor activity in patients with metastatic cancers of different histologies33. Here, CD177 is linked to metastatic malignant neoplasm.